Antibe Therapeutics (STU:4B70) Pretax Margin %: % (As of Dec. 2023)


STU:4B70 Antibe Therapeutics Inc STU:4B70
10 GF Score
Price €2.44
View Full Analysis

What is Antibe Therapeutics Pretax Margin %?

Antibe Therapeutics STU:4B70 10 Pretax Margin % is % as of Dec. 2023. GuruFocus rates STU:4B70 with a GF Score™ of 10/100.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Antibe Therapeutics's Pre-Tax Income for the three months ended in Dec. 2023 was €-2.88 Mil. Antibe Therapeutics's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, Antibe Therapeutics's pretax margin for the quarter that ended in Dec. 2023 was %.

The historical rank and industry rank for Antibe Therapeutics's Pretax Margin % or its related term are showing as below:


STU:4B70's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.895
* Ranked among companies with meaningful Pretax Margin % only.

Antibe Therapeutics  (STU:4B70) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Antibe Therapeutics Pretax Margin % Related Terms

Antibe Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Antibe Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics Pretax Margin % Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -132.93 -197.10 0.00 0.00 0.00

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:4B70 vs VRTX, REGN, SGEN: Pretax Margin % Comparison

For the Biotechnology subindustry, Antibe Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Pretax Margin % falls into.


STU:4B70
10GF Score
Antibe Therapeutics Inc STU:4B70
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibe Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Antibe Therapeutics's Pretax Margin for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-13.168/0
= %

Antibe Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-2.88/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Antibe Therapeutics (STU:4B70) has a Pretax Margin % of % as of Dec. 2023. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Antibe Therapeutics and its competitors.
Is Antibe Therapeutics' Pretax Margin % too high?
Antibe Therapeutics' current Pretax Margin % is %. Overall, Antibe Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Antibe Therapeutics' Pretax Margin % compare to VRTX and REGN?
Antibe Therapeutics' Pretax Margin % of % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Antibe Therapeutics and its competitors. Antibe Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibe Therapeutics stock overvalued right now?
Antibe Therapeutics (STU:4B70) has a current Pretax Margin % of %. The current Pretax Margin % is %. Antibe Therapeutics' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Antibe Therapeutics (STU:4B70), the current Pretax Margin % is % as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Antibe Therapeutics Business Description

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
10GF Score

Get the complete analysis for STU:4B70

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price